1. Home
  2. Browse
  3. HRA005063
HRA005063
   HRA005063.xlsx
Title:
Urinary tumor DNA MRD analysis to identify responders to neoadjuvant immunotherapy in muscle-invasive bladder cancer
Release date:
2023-07-27
Description:
Bladder preservation is a viable option for some muscle-invasive bladder cancer (MIBC) patients, but an effective noninvasive biomarker test to accurately identify promising candidates is lacking. Here we present the clinical application of a novel tissue-agnostic, urine-based minimal residual disease (MRD) assay in the neoadjuvant setting for personalized disease surveillance and actionable target identification to facilitate bladder-sparing treatment approaches.
Data Accessibility:   
Controlled access Request Data
BioProject:
PRJCA018203
Study type:
Disease Study
Disease name:
urinary bladder cancer
Data Access Committee

For each controlled access study, there is a corresponding Data Access Committee(DAC) to determine the access permissions. Access to actual data files is not managed by NGDC.


DAC NO.:
HDAC002826
DAC name:
I2N003-genomic-data
Contact person:
Xie Feng
Email:
fxie@huidumed.com
Description:
Bladder preservation is a viable option for some muscle-invasive bladder cancer (MIBC) patients, but an effective noninvasive biomarker test to accurately identify promising candidates is lacking. Here we present the clinical application of a novel tissue-agnostic, urine-based minimal residual disease (MRD) assay in the neoadjuvant setting for personalized disease surveillance and actionable target identification to facilitate bladder-sparing treatment approaches.
Individuals & samples
Files
Request Data
Submitter:   Chen Haige / rjbladder@163.com
Organization:   Renji Hospital, School of Medicine, Shanghai Jiao Tong University
Submission date:   2023-07-09
Requests:   -